Jeffrey Nau, PhD, MMS


Dr. Nau’s professional career has been primarily focused on developing novel and innovative therapies for diseases of the eye.  He brings more than 15 years of experience in the biotechnology, pharmaceutical, and medical device industry.  His most recent role was as the Vice President of Clinical and Medical Affairs at Ophthotech.  Prior to that he was a Medical Science Director at Genentech responsible for helping to develop Lucentis®, a transformative drug in the retina space.  Dr. Nau has built clinical and medical affairs teams at start-up companies such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc., raising more than $150 million in equity.  Dr. Nau holds a Master’s degree in Medical Science and a PhD in Public Health and Epidemiology.  He has numerous patents and peer-reviewed publications

Mark Murray


Mark has been in the life science sector for over 30 years working as a CFO and with senior executives and their boards.  His ophthalmology experience includes the successful exits of OptiMedica and Oculeve.  Mark spent over 20 years with Guidant Corporation and was part of Guidant’s senior management team and participated in its $1 billion IPO thru its exit in 2006 for $27 billion (by Boston Scientific and Abbott Labs).  He has participated in raising over $1.6 billion in equity and over $500 million in debt for both public and private companies.  Mark is currently a partner at partner at FLG Partners, LLC.  He holds a BS in business administration (accounting) from San Francisco State University.